製藥公司轉向運用人工智慧以加速藥物開發
Pharmaceutical companies turn to AI to speed up drug discovery
製藥行業目前正經歷一場巨大的變革，各大公司紛紛轉向人工智慧（AI），以解決「創新危機」。
The pharmaceutical industry is currently undergoing a massive transformation as companies turn to Artificial Intelligence to tackle the "innovation crisis."
傳統上，藥物研發是一個極其緩慢且昂貴的過程，通常需耗時十餘年，耗資數十億美元。
Traditionally, discovering a new drug is an incredibly slow and expensive process, often taking over a decade and costing billions of dollars.
AI 現在充當著「倍增器」的角色，讓研究人員能夠分析龐大的數據集，在幾天內而非數月內識別出生物標靶並設計出新分子。
AI is now acting as a "force multiplier," allowing researchers to analyze vast datasets to identify biological targets and design new molecules in days rather than months.
透過使用預測模型儘早篩除無效的候選藥物，公司可以節省大量時間與成本。
By using predictive modeling to filter out ineffective candidates early, companies can save substantial time and money.
新興的「AI 先行」生物科技公司正迫使傳統巨頭調整步伐或達成策略合作。
Newer "AI-first" biotech firms are forcing traditional giants to adapt or form strategic partnerships.
